新辅助化疗对晚期乳腺癌患者血浆 microRNA 及肿瘤相关指标的影响研究  

Effect of neoadjuvant chemotherapy on microRNA and tumor-related indicators in patients with advanced breast cancer

作　　者：石海洲[1] 王笃杰[1] 丁文贤[1] 许传屾[2] 

机构地区：[1]山东省滨州市中心医院,251700 [2]青岛大学医学院附属医院

出　　处：《中国实用医刊》2015年第22期4-6,共3页Chinese Journal of Practical Medicine

摘　　要：目的：分析新辅助化疗对晚期乳腺癌患者血浆microRNA及肿瘤相关指标的影响。方法收集晚期乳腺癌患者120例，随机分为新辅助化疗组（ NC组）和常规化疗组（ CC组），每组60例，分别纳入同时期良性乳腺病和健康志愿者各60例，作为良性对照组（ BC组）和健康对照组（ HC组）。对所有受试者血浆microRNA（ miR-31、miR-200c、miR-205）和肿瘤相关指标[可溶性白细胞介素-2受体（ sIL-2R）、白细胞介素-6（ IL-6）、血管内皮生长因子（ VEGF）]水平进行检测，比较组间差异。结果化疗前NC组和CC组血浆miR-31、miR-205表达水平显著低于良性乳腺病患者和健康志愿者，miR-200c、sIL-2R、IL-6和VEGF水平则显著高于BC组和HC组（P＜0.05）；晚期乳腺癌患者治疗效果与血浆miR-31、miR-205表达水平呈正相关，而与miR-200c、sIL-2R、IL-6和VEGF水平呈负相关。化疗后第15、45天，NC组血浆miR-31、miR-205表达水平显著高于CC组，miR-200c、sIL-2R、IL-6和VEGF水平则显著高于CC组（ P＜0.05）。结论新辅助化疗能有效上调晚期乳腺癌患者血浆miR-31、miR-205水平，下调miR-200c、sIL-2R、IL-6和VEGF水平，对晚期乳腺癌有改善作用。Objective To evaluate the effect of neoadjuvant chemotherapy on microRNA and tumor-related indicators in patients with advanced breast cancer.Methods One hundred and twenty pa-tients with advanced breast cancer were randomly divided into NC group and CC group with 60 cases in each group,and 60 patients with benign breast disease and 60 healthy volunteers in the same period were included as BC group and HC group.Then the plasma levels of miR-31, miR-200c, miR-205 and sIL-2R, IL-6, VEGF of all subjects were detected and compared.Results The plasma levels of miR-31 and miR-205 of NC group and CC group before treatment were lower than those of BC group and HC group, while the miR-200c and sIL-2R, IL-6, VEGF were higher than those of BC group and HC group（ P〈0.05 ） .The efficacy of treatment of advanced breast cancer patients was positively correlated to the plas-ma levels of miR-31, miR-205 expression, and negatively correlated to the plasma levels of miR-200c and sIL-2R, IL-6, VEGF.After 15, 45 days of chemotherapy, the plasma levels of miR-31, miR-205 expression of NC group were significantly higher than those of CC group, and miR-200c and sIL-2R, IL-6 , VEGF were significantly lower than those of CC group （ P 〈0.05 ） .Conclusions Neoadjuvant chemotherapy can effectively increase the plasma levels of miR-31, miR-205, and reduce the plasma lev-els of miR-200c and sIL-2R, IL-6, VEGF, so it is beneficial to improve the advanced breast cancer.

关 键 词：晚期乳腺癌 新辅助化疗 

分 类 号：R394.1[医药卫生—医学遗传学]